You started Wegovy® or Zepbound® three weeks ago and the scale has barely moved. Or you have not started yet, and you want to know when the weight will actually come off. Either way, you want a real timeline.
This guide is that timeline. It uses the published data from the STEP 1 trial of Wegovy® and the SURMOUNT-1 trial of Zepbound® to map out, week by week, when most people on these FDA-approved branded medications notice the appetite suppression kick in, when the scale starts moving in a meaningful way, and when the first plateau usually arrives.
All numbers below are from the published pivotal trials of the FDA-approved branded medications. Results apply only to the FDA-approved branded products studied; they do not apply to compounded preparations.
Key takeaways
Appetite suppression typically becomes noticeable in weeks 4 to 6 after the first dose step-up.
Meaningful scale movement on Wegovy® and Zepbound® usually shows up between weeks 8 and 16, as the dose climbs.
The average weight loss in the STEP 1 trial of Wegovy® was 14.9% at the 2.4 mg maintenance dose over 68 weeks. In the SURMOUNT-1 trial of Zepbound®, it was 22.5% at the 15 mg dose over 72 weeks.
Trial results cited here apply only to the FDA-approved branded Wegovy® and Zepbound® studied in those pivotal trials; they do not apply to compounded preparations.
Weeks 1 to 4: the acclimation phase
The first four weeks on Wegovy® or Zepbound® are an acclimation period. You are on the starter dose. The starter dose is intentionally below the therapeutic range for weight management; its only job is to let your body adjust to the slower gastric emptying that GLP-1 medications produce.
What you usually notice in weeks 1 to 4:
- Mild nausea, especially in the 24 to 48 hours after the injection
- Earlier fullness at meals, but not dramatic appetite changes
- Some food aversions, particularly to greasy or heavily processed foods
- Possibly mild fatigue
What you usually do not notice in weeks 1 to 4:
- Significant weight change — most people lose 1 to 3 pounds total in this window, mostly from reduced food intake plus water
- The dramatic appetite suppression people talk about — that arrives later
The starter dose of Wegovy® (0.25 mg) and Zepbound® (2.5 mg) is not therapeutic for weight management. The point of the first four weeks is to build tolerance, not to drive weight loss.
Weeks 5 to 8: the first therapeutic dose
This is where most people first feel Wegovy® or Zepbound® start to work for weight management. Your dose has stepped up to the first therapeutic level (0.5 mg of Wegovy® or 5 mg of Zepbound®). For most people, this is when:
- Appetite suppression becomes noticeable. Not extreme, but distinct.
- Portion sizes naturally drop. Half a sandwich feels like enough.
- Food noise (the constant background mental chatter about food) reduces.
- Weight starts moving. Most people drop 4 to 8 pounds total by the end of week 8.
Side effects often return briefly for a few days after the dose change, then settle.
Weeks 9 to 16: the steady-loss phase
Doses climb again at week 9 and week 13. This is the phase where the trial data for Wegovy® and Zepbound® shows the steepest part of the weight-loss curve. In the published STEP 1 trial of Wegovy® and the SURMOUNT-1 trial of Zepbound®, most participants saw their fastest week-over-week weight loss in this window.
Typical patterns in weeks 9 to 16:
- Steady weight loss of roughly 1 to 2 pounds per week, on average, across both branded medications
- Appetite suppression at its strongest — you may need to set reminders to eat enough protein
- Clothes start fitting differently
- Energy levels often improve as glycemic control stabilizes
| Week | Wegovy® (STEP 1 trial) | Zepbound® (SURMOUNT-1 trial) |
|---|---|---|
| Week 4 | ~2% | ~3% |
| Week 8 | ~5% | ~7% |
| Week 16 | ~9% | ~13% |
| Week 32 | ~12% | ~18% |
| Week 68 / 72 | 14.9% (final) | 22.5% (final) |
Approximate weight-loss percentages by trial week, from the published STEP 1 trial of Wegovy® (68 weeks total) and SURMOUNT-1 trial of Zepbound® (72 weeks total). Numbers are rounded averages from the trial curves. Results apply only to the FDA-approved branded products studied; they do not apply to compounded preparations.
Weeks 17 to 24: maintenance dose, first plateau
By week 17 most people are on the maintenance dose of Wegovy® (2.4 mg) or somewhere along the Zepbound® maintenance range (10 mg, 12.5 mg, or 15 mg). The first plateau is common in this window. A plateau on these medications usually lasts 2 to 4 weeks before the scale starts moving again.
Plateaus on Wegovy® or Zepbound® are not the medication failing. They are how the body recalibrates between phases of loss. Most people on these FDA-approved branded medications break through a plateau in 2 to 4 weeks without changing the dose.
Months 6 to 12: the long curve
From month 6 onward the rate of loss slows on both Wegovy® and Zepbound®, but the cumulative number keeps climbing. In the published STEP 1 trial of Wegovy®, participants kept losing weight steadily through week 68. In the SURMOUNT-1 trial of Zepbound®, the curve was steeper through week 72.
What this means practically: do not judge whether Wegovy® or Zepbound® is working by your month-1 weight loss. Judge by month 4, when the trajectory becomes clear, and by month 6, when the steady-state pattern emerges.
When the timeline diverges
Some people lose faster than the trial averages above. Some people lose slower. The variables that most often shape the timeline:
- Starting BMI. Higher starting BMI generally correlates with larger absolute weight loss on Wegovy® and Zepbound®, though the percentage tends to follow the trial averages.
- Dose tolerance. People who can stay on the maintenance dose of Wegovy® (2.4 mg) or the 15 mg dose of Zepbound® generally see results closest to the trial averages above. People who pause at a lower dose see proportionally less.
- Sleep and stress. Both blunt the GLP-1 effect over time. Sleep deprivation, in particular, can stall progress.
- Strength training plus protein intake. Protects lean mass during the rapid-loss phase, which preserves resting metabolism and helps the long curve.
- Type 2 diabetes status. The SURMOUNT-2 trial of Zepbound® in adults with type 2 diabetes showed a meaningfully smaller average weight loss than SURMOUNT-1 (in adults without type 2 diabetes). Diabetes status changes the expected curve on these branded medications.
A note on compounded preparations
Some licensed telehealth providers offer compounded preparations of semaglutide or tirzepatide instead of the FDA-approved branded Wegovy® and Zepbound®. Compounded preparations are made by state-licensed compounding pharmacies. They are not FDA-approved. They have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, the FDA-approved branded medications Wegovy®, Ozempic®, Mounjaro®, or Zepbound®. The trial timelines and weight-loss percentages discussed in this article apply only to the FDA-approved branded products studied; they do not apply to compounded preparations.
Frequently asked questions
Is no weight loss in week 1 a bad sign?
Not at all. Most people on Wegovy® or Zepbound® lose almost nothing in the first 2 weeks. The starter dose of either FDA-approved branded medication is below the therapeutic range for weight management. Real change usually shows up between weeks 5 and 8.
Will I keep losing weight as long as I stay on Wegovy® or Zepbound®?
The pivotal trials measured outcomes at 68 weeks (Wegovy®) and 72 weeks (Zepbound®). Most participants kept losing weight through the end of the trial, though the rate slowed over time. The long-term clinical understanding is that these FDA-approved branded medications need to be continued long-term to maintain the weight loss observed in the trials.
What if I hit a plateau and stay there?
Plateaus of 2 to 4 weeks are normal on Wegovy® and Zepbound®. A plateau lasting more than 6 weeks is worth a conversation with your prescriber. Common adjustments include increasing the dose if you are below the maintenance dose, reviewing protein intake, adding resistance training, or addressing a sleep deficit.
Can I lose weight faster if I eat very little while on Wegovy® or Zepbound®?
Eating very little on top of an FDA-approved branded GLP-1 medication tends to backfire. Severe caloric restriction signals the body to slow metabolism, which dampens the effect of Wegovy® or Zepbound®. Most prescribers recommend a moderate deficit (300 to 500 calories below maintenance), adequate protein (0.7 to 1.0 g per pound of goal body weight), and strength training during the loss phase.
What is the difference between losing on Wegovy® and losing on Zepbound®?
The pivotal trials of these two FDA-approved branded medications showed different average percentages: 14.9% in the STEP 1 trial of Wegovy® and 22.5% in the SURMOUNT-1 trial of Zepbound® at their respective top doses. The curves track each other for the first 4 to 6 weeks and diverge after week 8 as the dose climbs. People who can tolerate the top dose of Zepbound® generally see the largest losses.
What about the 5% threshold?
Clinicians often treat 5% loss of body weight as the threshold where weight-related health markers start to improve meaningfully. In the published trials of Wegovy® and Zepbound®, most participants crossed 5% loss between week 12 and week 16 of treatment.
Sources
- Wilding JPH, et al. STEP 1 trial of Wegovy® (semaglutide brand). New England Journal of Medicine. 2021. PubMed 33567185
- Jastreboff AM, et al. SURMOUNT-1 trial of Zepbound® (tirzepatide brand). New England Journal of Medicine. 2022. PubMed 35658024
- Garvey WT, et al. SURMOUNT-2 trial of Zepbound® (tirzepatide brand) in adults with type 2 diabetes. The Lancet. 2023. PubMed 37356445
- U.S. Food and Drug Administration. Wegovy® Prescribing Information. 2024 revision. fda.gov
- U.S. Food and Drug Administration. Zepbound® Prescribing Information. 2024 revision. fda.gov
Last updated: 2026-06-11 · Editorially reviewed by the Peptides.io team
Important notices & disclaimers
Editorial & medical: This guide is general education, not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.
Affiliate disclosure: Peptides.io may earn a commission from links to providers — it never changes what you pay or how we rank them, and never influences our recommendations.
Compounded GLP-1 (FDA): Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, branded medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Clinical-trial results cited here apply only to those branded formulations — not to compounded preparations.
See the top Weight Loss brands, compared
The real providers we've vetted — scored side by side, so you can pick what fits your goal and get started, not just read.
See the picks →
Comments